Literature DB >> 21670926

Physician adherence to guidelines for tuberculosis and HIV care in Rio de Janeiro, Brazil.

Valeria Saraceni1, Antonio Guilherme Pacheco, Jonathan E Golub, Vitoria Vellozo, Bonnie S King, Solange C Cavalcante, Lois Eldred, Richard E Chaisson, Betina Durovni.   

Abstract

BACKGROUND: Tuberculosis is the most common opportunistic infection among HIV-infected patients in Brazil. Brazil's national policy for HIV care recommends screening for latent tuberculosis (TB) and implementing isoniazid preventive therapy (IPT).
OBJECTIVES: We compared physician adherence to TB screening and other prevention and care policies among HIV primary care clinics in Rio de Janeiro City.
METHODS: Data on performance of CD4 counts, viral load testing, tuberculin skin testing (TST) and IPT were abstracted from patient charts at 29 HIV clinics in Rio de Janeiro as part of the TB/HIV in Rio (THRio) study. Data on use of pneumocystis jiroveci pneumonia (PCP) prophylaxis were also abstracted from a convenience sample of 150 patient charts at 10 HIV clinics. Comparisons were made between rates of adherence to TB guidelines and other HIV care guidelines.
RESULTS: Among the subset of 150 patients with confirmed HIV infection in 2003, 96% had at least one reported CD4 counts result; 93% had at least one viral load result reported; and, PCP prophylaxis was prescribed for 97% of patients with CD4 counts < 200 cells/mm³ or when clinically indicated. In contrast, 67 patients (45%) had a TST performed (all eligible); and only 11% (17) of eligible patients started IPT. Among 12,027 THRio cohort participants between 2003 and 2005, the mean number of CD4 counts and viral load counts was 2.5 and 1.9, respectively, per patient per year. In contrast, 49% of 8,703 eligible patients in THRio had a TST ever performed and only 53% of eligible patients started IPT.
CONCLUSION: Physicians are substantially more compliant with HIV monitoring and PCP prophylaxis than with TB prophylaxis guidelines. Efforts to improve TB control in HIV patients are badly needed.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21670926     DOI: 10.1016/s1413-8670(11)70184-2

Source DB:  PubMed          Journal:  Braz J Infect Dis        ISSN: 1413-8670            Impact factor:   1.949


  6 in total

1.  Risk factors for treatment default in close contacts with latent tuberculous infection.

Authors:  C T Fiske; F-X Yan; Y Hirsch-Moverman; T R Sterling; M R Reichler
Journal:  Int J Tuberc Lung Dis       Date:  2014-04       Impact factor: 2.373

2.  Cost-effectiveness of tuberculosis screening and isoniazid treatment in the TB/HIV in Rio (THRio) Study.

Authors:  M Azadi; D M Bishai; D W Dowdy; L H Moulton; S Cavalcante; V Saraceni; A G Pacheco; S Cohn; R E Chaisson; B Durovni; J E Golub
Journal:  Int J Tuberc Lung Dis       Date:  2014-12       Impact factor: 2.373

3.  Prevalent tuberculosis at HIV diagnosis in Rio de Janeiro, Brazil: the TB/HIV in Rio (THRio) Cohort.

Authors:  Valeria Saraceni; Silvia Cohn; Solange C Cavalcante; Antonio G F Pacheco; Lawrence H Moulton; Richard E Chaisson; Betina Durovni; Jonathan E Golub
Journal:  J Acquir Immune Defic Syndr       Date:  2014-09-01       Impact factor: 3.731

4.  Barriers to tuberculosis and human immunodeficiency virus treatment guidelines adherence among nurses initiating and managing anti-retroviral therapy in KwaZulu-Natal and North West provinces.

Authors:  Lufuno Makhado; Mashudu Davhana-Maselesele; Jason E Farley
Journal:  Curationis       Date:  2018-03-26

5.  Access and adherence to isoniazid preventive therapy and occurrence of active TB in a cohort of people living with HIV: a retrospective cohort study in Sao Paulo, Brazil.

Authors:  Camila Melo Picone; Angela Carvalho Freitas; Eliana B Gutierrez; Vivian Iida Avelino-Silva
Journal:  Rev Inst Med Trop Sao Paulo       Date:  2020-02-07       Impact factor: 1.846

6.  Is it time for Brazil to prioritize TB preventive therapy for all people living with HIV?

Authors:  Ethel L Maciel; Thiago N do Prado; Kleydson Bonfim Andrade; Jonathan E Golub
Journal:  Braz J Infect Dis       Date:  2017-11-06       Impact factor: 3.257

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.